Homepage
Author:
Humacyte, Inc
Posted Date:
March 27, 2026
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
Humacyte, Inc
March 27, 2026
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
Humacyte, Inc
March 26, 2026
Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026
Humacyte, Inc
March 23, 2026
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
Humacyte, Inc
March 19, 2026
Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia
Humacyte, Inc
March 19, 2026
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair
Humacyte, Inc
March 17, 2026
Humacyte To Participate in Upcoming Investor Conferences
Humacyte, Inc
March 2, 2026
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
Humacyte, Inc
February 18, 2026
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
Humacyte, Inc
February 9, 2026
